| Literature DB >> 26999116 |
Zbynek Heger1,2, Jaromir Gumulec3, Ales Ondrak4, Jan Skoda5, Zdenek Zitka6, Natalia Cernei7,8, Michal Masarik9,10, Ondrej Zitka11,12, Vojtech Adam13,14.
Abstract
Herein, we present a study focused on the determination of the influence of long-distance (53 km) bicycle riding on levels of chosen biochemical urinary and serum prostate cancer (PCa) biomarkers total prostate-specific antigen (tPSA), free PSA (fPSA) and sarcosine. Fourteen healthy participants with no evidence of prostate diseases, in the age range from 49-57 years with a median of 52 years, underwent physical exercise (mean race time of 150 ± 20 min, elevation increase of 472 m) and pre- and post-ride blood/urine sampling. It was found that bicycle riding resulted in elevated serum uric acid (p = 0.001, median 271.76 vs. 308.44 µmol/L pre- and post-ride, respectively), lactate (p = 0.01, median 2.98 vs. 4.8 mmol/L) and C-reactive protein (p = 0.01, 0.0-0.01 mg/L). It is noteworthy that our work supports the studies demonstrating an increased PSA after mechanical manipulation of the prostate. The subjects exhibited either significantly higher post-ride tPSA (p = 0.002, median 0.69 vs. 1.1 ng/mL pre- and post-ride, respectively) and fPSA (p = 0.028, median 0.25 vs. 0.35 ng/mL). Contrary to that, sarcosine levels were not significantly affected by physical exercise (p = 0.20, median 1.64 vs. 1.92 µmol/mL for serum sarcosine, and p = 0.15, median 0.02 µmol/mmol of creatinine vs. 0.01 µmol/mmol of creatinine for urinary sarcosine). Taken together, our pilot study provides the first evidence that the potential biomarker of PCa-sarcosine does not have a drawback by means of a bicycle riding-induced false positivity, as was shown in the case of PSA.Entities:
Keywords: lactate; metabolism; physical exercise; prostate-specific antigen; sarcosine
Mesh:
Substances:
Year: 2016 PMID: 26999116 PMCID: PMC4813236 DOI: 10.3390/ijms17030377
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Anthropometric characteristics of the cohort; results of the Wilcoxon matched pairs test.
| Parameter | Before (Median, Interquartile Range) | After (Median, Interquartile Range) | |
|---|---|---|---|
| Muscles (%) | 35.55 (33.1–38.4) | 34.6 (32.5–37.6) | 0.01 |
| Fat (%) | 22.5 (16.4–25.5) | 22.75 (18.4–27.3) | 0.01 |
| Temperature (°C) | 36.4 (36.2–36.6) | 36.1 (36–36.3) | 0.08 |
| Body mass index (BMI) (kg/m2) | 25.9 (23.6–27.7) | 25.9 (23.8–27.4) | 0.10 |
| Systolic pressure (mmHg) | 143 (136–149) | 130 (123–137) | 0.01 |
| Diastolic pressure (mmHg) | 93 (79–99) | 87 (78–96) | 0.10 |
Figure 1Effect of physical exercise on anthropometric parameters, expressed as box plots for: (A) total muscles; (B) systolic pressure; and (C) diastolic pressure. The middle lines in the figures indicate the median values.
Serum markers of tested cohorts; results of the Wilcoxon matched pairs test.
| Parameter | Before (Median, Interquartile Range) | After (Median, Interquartile Range) | |
|---|---|---|---|
| Testosterone (nmol/L) | 6.9 (5.1–11.7) | 8.5 (5.9–9.4) | 0.727 |
| Triglycerides (mmol/L) | 1.7 (1.35–2.14) | 1.6 (1.32–1.97) | 0.81 |
| ALP (µkat/L) | 0.53 (0.5–1.29) | 0.87 (0.46–1.06) | 0.75 |
| ALT (µkat/L) | 0.54 (0.47–0.64) | 0.52 (0.49–0.56) | 0.31 |
| AST (µkat/L) | 0.43 (0.41–0.5) | 0.48 (0.43–0.51) | 0.13 |
| GMT (µkat/L) | 0.46 (0.38–0.69) | 0.45 (0.34–0.75) | 0.55 |
| Cholesterol (mmol/L) | 5.75 (5.34–6.21) | 5.9 (5.28–6.34) | 0.14 |
| Bilirubin (µmol/L) | 7.35 (6.38–10.33) | 9.8 (7.92–10.93) | 0.60 |
| Glucose (mmol/L) | 4.93 (4.56–5.17) | 4.48 (4.38–4.99) | 0.20 |
| Total protein (g/L) | 65.48 (62.26–66.36) | 65.71 (64.04–67.2) | 0.31 |
| Creatinine (µmol/L) | 100.74 (96.9–103.9) | 103.21 (95.02–109.31) | 0.42 |
ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate transaminase; GMT: γ glutamyltransferase.
Figure 2Effect of physical exercise on biochemical parameters, expressed as box plots for: (A) serum uric acid; (B) serum lactate; and (C) serum C-reactive protein (CRP). The middle lines in the figures indicate the median values.
Urinary markers of tested cohorts; results of the Wilcoxon matched pairs test.
| Parameter | Before (Median, Interquartile Range) | After (Median, Interquartile Range) | |
|---|---|---|---|
| pH | 5.7 (5.1–6) | 5.1 (4.8–5.5) | 0.04 |
| Potassium (mmol/mmol) * | 32 (23–38) | 28.5 (17–43) | 0.75 |
| Chlorides (mmol/mmol) * | 244.5 (187–294) | 204.5 (137–247) | 0.08 |
| Sodium (mmol/mmol) * | 118 (79–178) | 113 (56–164) | 0.51 |
| Total protein (g/L) | 16.65 (12–32.1) | 17.8 (11.5–25) | 0.27 |
| Creatinine (mmol/L) | 6.96 (5.2–8.29) | 6.59 (3.64–8.7) | 0.78 |
| Valine (µmol/mmol) * | 13.35 (7.9–24.4) | 13.2 (3.8–25.3) | 0.62 |
| Tyrosine (µmol/mmol) * | 9.25 (3.8–17.3) | 6.55 (4.1–14.6) | 0.40 |
| Threonine (µmol/mmol) * | 10.4 (1.8–19.4) | 9.55 (5.8–19.5) | 0.59 |
| Serine (µmol/mmol) * | 6.95 (3.5–11.6) | 6.45 (3.6–9.5) | 0.30 |
| Proline (µmol/mmol) * | 4.6 (3.3–9.7) | 4.75 (2.8–9.8) | 0.83 |
| Phenylalanine (µmol/mmol) * | 7.95 (6.2–15.2) | 8.35 (5.1–16.6) | 1.00 |
| Methionine (µmol/mmol) * | 5.15 (2.4–10.4) | 5.25 (2.6–11.3) | 0.64 |
| Lysine (µmol/mmol) * | 49.6 (38.6–85.6) | 51.5 (34.1–130.1) | 0.20 |
| Leucine (µmol/mmol) * | 4.05 (0.9–9.8) | 2 (0.8–3.5) | 0.11 |
| Isoleucine (µmol/mmol) * | 4.6 (1–9.5) | 5.35 (2.6–7.7) | 0.97 |
| Histidine (µmol/mmol) * | 14.75 (3.6–50.6) | 11.5 (7.2–44.8) | 0.36 |
| Glycine (µmol/mmol) * | 6.3 (3–13) | 7.35 (3.9–11.1) | 0.36 |
| Glutamic acid (µmol/mmol) * | 3.45 (1.1–6) | 3.5 (1.3–7.3) | 0.81 |
| Cysteine (µmol/mmol) * | 4.2 (2.8–10.4) | 4.45 (1.8–5.3) | 0.64 |
| Aspartic acid (µmol/mmol) * | 27.5 (15.6–64.2) | 33 (20.1–66.7) | 0.55 |
| Arginine (µmol/mmol) * | 39.55 (16.3–61.7) | 30.3 (18.6–38.1) | 0.06 |
| Alanine (µmol/mmol) * | 3.55 (1.9–6.3) | 4.25 (1.7–7.2) | 0.25 |
* Values are normalized to mmol of creatinine.
Figure 3Effect of physical exercise on biomarkers of prostate cancer (PCa), expressed as box plots for: (A) serum total prostate-specific antigen (tPSA); (B) serum free PSA (fPSA); (C) serum sarcosine; and (D) urinary sarcosine. The middle lines in the figures indicate the median values.
Figure 4Schematic depiction of the formation of PSA variants and kallikrein-related peptidase 2 (hK2). hK2 proteolytic activity probably removes propeptides from PSA, forming its mature, catalytic form. Secreted PSA is complexed or enzymatically inactivated to form free PSA forms (nicked PSA (nPSA), proenzyme form of PSA (proPSA) and intact PSA) and complexed PSA (PSA complex with ACT (1-antichymotrypsin)). In normal conditions (N), cells in the prostate are healthy and organized in a tight pattern. Hence, only a small amount of PSA leaks into the bloodstream. In prostate cancer (PCa), cells are disorganized, and the layers between the prostate and bloodstream become disrupted. Thus, more PSA is leaked into the blood. During bicycle riding (BR), cells are likely irritated and forming the pores for the transient leakage of PSA into blood. This phenomenon can significantly affect the clinical performance of PSA. The dotted arrows represent the transition of molecules from the intracellular to the extracellular regions.
Figure 5Profile of the physical exercise (bicycle riding) performed to evaluate the differences between anthropometric and biochemical parameters.